Aurinia Pharmaceuticals Cash Flow Statement
NASDAQ: AUPHHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Aurinia Pharmaceuticals free cash flow
In fiscal 2025, Aurinia Pharmaceuticals generated $135.7 million of operating cash flow. That left free cash flow of $135.7 million, a free-cash-flow margin of 47.9% of revenue. Free cash flow was up 205.6% from the prior year's $44.4 million.
Aurinia Pharmaceuticals returned $98.2 million to shareholders through share repurchases, equal to 72% of free cash flow.
Summary generated from market data by MetaCap's automated system. Methodology
Aurinia Pharmaceuticals cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 287.20M | 5.75M | -78.02M | -108.18M | -180.97M | -102.68M | -88.39M | -53.08M | -70.79M | -23.30M |
| Net Income growth (YoY) | +4893.08% | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 19.45M | 19.45M | 11.65M | 2.71M | 2.76M | 1.37M | 33.00K | 20.00K | — | — |
| Stock-Based Compensation | 14.68M | 31.60M | 45.31M | 32.30M | 31.24M | 17.45M | 7.41M | 6.86M | 4.24M | 1.38M |
| Change in Working Capital | -9.58M | -5.33M | -21.47M | -4.89M | -16.98M | -957.00K | 3.85M | -995.00K | — | — |
| Operating Cash Flow | 135.66M | 44.39M | -33.46M | -79.53M | -157.69M | -69.86M | -63.59M | -51.61M | -41.17M | -18.71M |
| Capital Expenditures | — | — | — | — | — | — | -87.00K | -30.00K | -25.00K | -15.00K |
| Investing Cash Flow | -32.77M | 39.26M | -6.71M | -60.63M | -103.87M | -158.19M | 7.78M | -65.00K | -8.00M | 9.99M |
| Share Repurchases | -98.16M | -40.24M | 0 | 0 | — | — | — | — | — | — |
| Financing Cash Flow | -106.11M | -49.09M | -5.13M | 2.43M | 221.11M | 194.38M | 243.85M | 4.01M | 175.15M | 42.62M |
| Net Change in Cash | -3.22M | 34.56M | -45.30M | -137.73M | -40.45M | -33.67M | 188.05M | -47.66M | 125.98M | 33.89M |
| Free Cash Flow | 135.66M | 44.39M | -33.46M | -79.53M | -157.69M | -69.86M | -63.67M | -51.64M | -41.19M | -18.73M |
This table shows 10 annual periods of Aurinia Pharmaceuticals's cash flow statement, from FY 2025 back to FY 2016, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow AUPH's reporting calendar. What is a cash flow statement?